Sean F. Scanlan - 15 Feb 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Chief Innovation Officer
Signature
/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan
Issuer symbol
TMCI
Transactions as of
15 Feb 2023
Net transactions value
-$542,235
Form type
4
Filing time
17 Feb 2023, 20:00:17 UTC
Previous filing
13 Jan 2023
Next filing
10 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Options Exercise $2,500 +25,000 +251% $0.1000* 34,975 15 Feb 2023 Direct F1, F2
transaction TMCI Common Stock Sale $542,235 -25,000 -71% $21.69 9,975 15 Feb 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option (Right to Buy) Options Exercise $2,500 -25,000 -30% $0.1000* 58,750 15 Feb 2023 Common Stock 25,000 $0.1000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Includes 9,975 RSUs.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.5000 to $21.9900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.